Small lymphocytic lymphoma

The PBS subsidises idelalisib for patients with small lymphocytic lymphoma (SLL).

Idelalisib can be subsidised through the PBS under section 85 of the National Health Act 1953 for patients with small lymphocytic lymphoma.

Patient eligibility

Patients must meet the relevant criteria in the restrictions and be eligible for the PBS.

The Schedule of Pharmaceutical Benefits on the PBS website outlines restrictions for prescribing idelalisib.


Initial treatment

Make all initial applications for authority approval to prescribe PBS subsidised idelalisib for the treatment of small lymphocytic lymphoma in writing and:

All applications must include a completed:

Continuing treatment

Applications for continuing treatment can be made by calling the PBS Complex Drugs Programs enquiry line.

Further information

For more information call the PBS Complex Drugs Programs enquiry line.

Page last updated: 1 October 2017